Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Meets DSM-IV criteria for opioid dependence~2. Age \> 18 years~3. Confirmed HIV infection, either through positive HIV antibody or detectable HIV-1 RNA level.~4. Within the Connecticut Department of Corrections (CTDOC) or Hampden County Correctional Center (HCCC) and within 30 days of being released to the greater New Haven, Hartford or Springfield areas or within 30 days after release from CTDOC or HCCC.~5. No participation in pharmacotherapy trial in the previous 30 days~6. Not pregnant~Exclusion Criteria:~1. Unable to provide informed consent~2. Verbally or physically threatening to research staff~3. Unable to communicate in either English or Spanish~4. Pending trials for a felony~5. Liver failure (Childs-Pugh Class B or C Cirrhosis)~6. Grade IV Hepatitis (liver function tests \> 10X normal)~7. Receiving opioid prescription narcotics or has pain syndrome necessitating future use of opioid prescription narcotics.~8. Receiving active methadone or buprenorphine/naloxone for the treatment of opioid dependency~9. Active opioid withdrawal (within 3-5 days since last opioid ingestion)~10. Pregnancy or unwilling to take contraceptives measures~11. Breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Extended-Release Naltrexone (Type: ACTIVE_COMPARATOR): Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release

Based on this trial design, predict the completion outcome and termination type (if applicable).